EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-18	180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18)	2020-05-14
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-30	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-30)	2020-05-14
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-31	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-31)	2020-05-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

The synergistic combination of efavirenz, lamivudine, and tenofovir disoproxil fumarate constitutes a cornerstone in antiretroviral therapy (ART) for HIV-1 treatment. Ensuring access to high-quality, reliable suppliers for these pharmaceuticals is essential for healthcare providers, governments, and pharmaceutical companies aiming to maintain uninterrupted treatment regimens. This report provides an in-depth overview of global suppliers for these medicines, highlighting manufacturing sources, regulatory statuses, and market dynamics.

Efavirenz: Supplier Landscape

Manufacturers and Key Contributors

Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), has several prominent manufacturers worldwide. Leading suppliers include:

Mylan (now Viatris): One of the most prolific producers, with formulations approved in multiple regions, including the United States and Europe. Mylan supplies generic efavirenz to global markets, with production plants adhering to cGMP standards.
Hetero Labs Limited: Based in India, Hetero is a significant supplier of generic efavirenz, with WHO prequalification and approvals from regulatory agencies such as the USFDA and EMA.
Aurobindo Pharma: Another Indian manufacturer with WHO prequalification, supplying efavirenz generics to developing nations.
Janssen Pharmaceuticals: The originator of efavirenz as part of the brand name drug Sustiva. Janssen's production is primarily for branded markets, with licensed generics in select regions.

Regulatory and Quality Assurance

Efavirenz suppliers must meet stringent quality standards, including WHO prequalification and USFDA approval, particularly for procurement through global health initiatives like PEPFAR and the Global Fund. Many Indian manufacturers have attained these certifications, which facilitate international distribution.

Market Dynamics

The demand for efavirenz has shifted in recent years, influenced by the emergence of integrase inhibitors like dolutegravir. Nonetheless, efavirenz remains a vital component in low- and middle-income country (LMIC) markets due to its cost-effectiveness and established supply chains.

Lamivudine: Supplier Landscape

Leading Manufacturers

Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), is produced by numerous pharmaceutical firms:

MLS (Matrix Laboratories / Mylan): A dominant supplier with WHO-prequalified formulations, especially notable for their affordable generic versions.
Hetero Labs and Aurobindo Pharma: Indian-based manufacturers with extensive global reach, compliant with regulatory standards and holding WHO prequalification.
Gilead Sciences: Originally developed lamivudine as a branded product (Epivir), with production primarily for branded markets. Gilead's generics are licensed in many regions, but the company is also noted for patent management strategies that influence supply dynamics.

Regulatory Standards

Most suppliers distributing lamivudine in global markets possess WHO prequalification or approval from major regulators such as the USFDA, EMA, or South African Health Products Regulatory Authority (SAHPRA). This ensures the drug's quality, efficacy, and safety for vulnerable populations.

Market Dynamics

Generics dominate the lamivudine supply landscape, driven by high demand in ART regimens. Indian manufacturers, leveraging cost-effective synthesis and manufacturing, serve as primary suppliers for LMICs. Supply stability is generally high due to the mature manufacturing infrastructure.

Tenofovir Disoproxil Fumarate: Supplier Landscape

Major Manufacturers

Tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor (NRTI), is produced by several key players:

Gilead Sciences: As the patent holder and original developer of TDF, Gilead supplies branded formulations (Viread) and has licensed generic production in many markets post-patent expiry.
Indian Generic Manufacturers (e.g., Hetero, Aurobindo, Cipla): After patent expiration, these firms obtained WHO prequalification and USFDA approval to produce TDF generics, significantly increasing global supply and reducing costs.
Fujifilm Toyama Chemical: Notable for manufacturing TDFs for the Japanese and certain Asian markets, with strict regulatory adherence.

Regulatory and Quality Certification

Given Gilead's patent rights, licensed generics from Indian manufacturers often operate under voluntary licensing agreements, enabling them to produce WHO-prequalified TDF. This practice supports affordable access in resource-limited settings.

Supply and Market Trends

The patent expiry of TDF in many jurisdictions has markedly increased global supply capabilities. This has contributed to expanded access, especially in LMICs. However, the transition to newer formulations, such as tenofovir alafenamide (TAF), is gradually shifting the market focus.

Global Supply Chain and Market Considerations

The global supply of efavirenz, lamivudine, and tenofovir disoproxil fumarate is characterized by a collaborative interplay between originator companies, generic manufacturers, and regulatory agencies. Indian pharmaceutical firms dominate the manufacturing sector for generics, notably due to their cost competitiveness and regulatory compliance, which contribute significantly to HIV/AIDS treatment programs worldwide.

Most suppliers meet WHO prequalification standards, ensuring consistent drug quality critical for public health programs. The supply chain is also subject to geopolitical factors, patent considerations, and stockpiling strategies that influence availability and pricing.

Impact of Patent Laws and Licensing

Patents historically constrained generic manufacturing of efavirenz and TDF. However, patent expirations have facilitated increased generic competition, lowering prices and expanding access. Gilead's voluntary licensing agreements have further enhanced global procurement of TDF, especially in countries participating in such initiatives.

Future Outlook

Emerging formulations like tenofovir alafenamide (TAF) are gradually replacing TDF in certain markets, altering the supplier landscape. Additionally, the development of long-acting formulations and fixed-dose combinations (FDCs) continue to diversify supply sources.

Key Takeaways

Dominance of Indian Manufacturers: Indian companies such as Hetero, Aurobindo, Cipla, and Mylan are primary suppliers of efavirenz, lamivudine, and tenofovir disoproxil fumarate, supported by WHO prequalification and regulatory approvals.
Patent Expiry and Generics: Patent expiration of efavirenz and TDF has expanded the supplier base, increasing supply and reducing costs, crucial for global HIV treatment programs.
Regulatory Standards Are Critical: Suppliers with WHO prequalification and USFDA approval ensure drug quality necessary for international procurement and public health initiatives.
Market Evolution: With the rise of alternative drugs and formulations, supplier focus is shifting towards TAF and long-acting injectables, while traditional drugs remain essential in LMICs.
Supply Chain Stability: Diversification of suppliers and adherence to regulatory standards sustain supply continuity, mitigating risks related to geopolitical or patent disputes.

FAQs

1. Who are the leading global suppliers of efavirenz?
Indian manufacturers such as Hetero Labs, Aurobindo Pharma, and Mylan are among the leading suppliers, supported by WHO prequalification, with Janssen Pharmaceuticals as the originator supplier for branded formulations.

2. Are lamivudine and tenofovir disoproxil fumarate available as generic drugs?
Yes, extensive generic manufacturing, predominantly by Indian firms, provides lamivudine and tenofovir disoproxil fumarate globally, bolstered by patent expirations and voluntary licensing agreements.

3. How does patent law influence the availability of these drugs?
Patent laws historically limited generic competition, but patent expirations in recent years have facilitated increased generic production, lowering costs and expanding access.

4. What regulatory standards ensure the quality of these pharmaceuticals?
WHO prequalification, USFDA approval, and approvals by regional authorities like EMA or SAHPRA ensure these medications meet international safety and efficacy standards.

5. What is the future trend for suppliers of these HIV drugs?
Emergence of new formulations like tenofovir alafenamide and long-acting injectables will influence supplier focus, but traditional drugs will remain critical, particularly in resource-limited settings, with Indian generics maintained as the primary supply source.

References

WHO Prequalification of Medicines Program, "Efavirenz," [Online]. Available: https://www.who.int/medicines/services/expertcommittees/pharmlist/en/
US Food and Drug Administration, "Approved Drugs," [Online]. Available: https://www.fda.gov/drugs/drug-approvals-and-databases
Global Fund, "Procurement and Supply Chain Management," [Online]. Available: https://www.theglobalfund.org/en/procurement/
Gilead Sciences, "Viread (Tenofovir Disoproxil Fumarate) Official Website," [Online]. Available: https://www.gilead.com/
Indian Ministry of Chemicals & Fertilizers, "Pharmaceutical Manufacturing," [Online]. Available: https://chemicals.gov.in/content/pharmaceuticals

By synthesizing the current landscape of suppliers for efavirenz, lamivudine, and tenofovir disoproxil fumarate, this report provides stakeholders with actionable insights crucial for program planning, procurement strategies, and market forecasts.

Suppliers and packagers for generic pharmaceutical drug: EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE